Rua Life Sciences PLC (RUA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rua Life Sciences PLC (RUA) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX29.00K ≈ $3.53 USD) by net assets (GBX7.18 Million ≈ $874.21 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Rua Life Sciences PLC net asset quality index to measure how much of total assets are equity-financed.
Rua Life Sciences PLC - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Rua Life Sciences PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Rua Life Sciences PLC to evaluate the quality of earnings relative to operating cash generation.
Rua Life Sciences PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rua Life Sciences PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Conygar Investment Co PLC
LSE:CIC
|
0.092x |
|
Trustco Group Holdings
JSE:TTO
|
-0.004x |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
0.024x |
|
Roquefort Investments PLC
LSE:ROQ
|
-0.069x |
|
Sable Exploration and Mining Ltd
JSE:SXM
|
N/A |
|
Sprott Physical Uranium Trust
TO:U-U
|
0.000x |
|
Creightons Plc
LSE:CRL
|
0.032x |
|
Shearwater Group plc
LSE:SWG
|
-0.070x |
Annual Cash Flow Conversion Efficiency for Rua Life Sciences PLC (1994–2025)
The table below shows the annual cash flow conversion efficiency of Rua Life Sciences PLC from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see RUA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | GBX7.23 Million ≈ $879.44 |
GBX-137.00K ≈ $-16.67 |
-0.019x | +36.02% |
| 2025-03-31 | GBX7.39 Million ≈ $899.39 |
GBX-219.00K ≈ $-26.65 |
-0.030x | +83.98% |
| 2024-03-31 | GBX7.18 Million ≈ $873.84 |
GBX-1.33 Million ≈ $-161.58 |
-0.185x | +26.24% |
| 2023-03-31 | GBX4.68 Million ≈ $569.79 |
GBX-1.17 Million ≈ $-142.84 |
-0.251x | +30.09% |
| 2022-03-31 | GBX6.58 Million ≈ $801.08 |
GBX-2.36 Million ≈ $-287.27 |
-0.359x | -114.35% |
| 2021-03-31 | GBX8.51 Million ≈ $1.03K |
GBX-1.42 Million ≈ $-173.14 |
-0.167x | +11.70% |
| 2020-03-31 | GBX2.27 Million ≈ $276.80 |
GBX-431.00K ≈ $-52.44 |
-0.189x | -32.48% |
| 2019-03-31 | GBX3.00 Million ≈ $365.01 |
GBX-429.00K ≈ $-52.20 |
-0.143x | -141.87% |
| 2018-03-31 | GBX1.02 Million ≈ $123.62 |
GBX347.00K ≈ $42.22 |
0.342x | +325.07% |
| 2017-03-31 | GBX1.05 Million ≈ $127.99 |
GBX-159.62K ≈ $-19.42 |
-0.152x | -318.79% |
| 2016-03-31 | GBX1.22 Million ≈ $148.59 |
GBX84.70K ≈ $10.31 |
0.069x | +158.98% |
| 2015-03-31 | GBX1.61 Million ≈ $196.39 |
GBX-189.82K ≈ $-23.10 |
-0.118x | -708.78% |
| 2014-03-31 | GBX1.65 Million ≈ $200.81 |
GBX-24.00K ≈ $-2.92 |
-0.015x | -111.36% |
| 2013-03-31 | GBX2.71 Million ≈ $329.20 |
GBX346.19K ≈ $42.12 |
0.128x | +703.72% |
| 2012-03-31 | GBX3.18 Million ≈ $386.67 |
GBX50.59K ≈ $6.16 |
0.016x | +103.25% |
| 2011-03-31 | GBX3.12 Million ≈ $379.86 |
GBX-1.53 Million ≈ $-185.79 |
-0.489x | -29.15% |
| 2010-03-31 | GBX5.41 Million ≈ $658.61 |
GBX-2.05 Million ≈ $-249.43 |
-0.379x | -67.19% |
| 2009-03-31 | GBX6.13 Million ≈ $746.09 |
GBX-1.39 Million ≈ $-169.00 |
-0.227x | -41.48% |
| 2008-03-31 | GBX7.11 Million ≈ $865.57 |
GBX-1.14 Million ≈ $-138.58 |
-0.160x | +41.90% |
| 2007-03-31 | GBX2.96 Million ≈ $360.27 |
GBX-816.00K ≈ $-99.28 |
-0.276x | -9.29% |
| 2006-03-31 | GBX5.11 Million ≈ $621.50 |
GBX-1.29 Million ≈ $-156.71 |
-0.252x | +32.73% |
| 2005-03-31 | GBX5.65 Million ≈ $687.81 |
GBX-2.12 Million ≈ $-257.82 |
-0.375x | -192.12% |
| 2004-03-31 | GBX7.57 Million ≈ $920.69 |
GBX-971.00K ≈ $-118.14 |
-0.128x | +92.57% |
| 2003-03-31 | GBX6.91 Million ≈ $840.50 |
GBX-11.93 Million ≈ $-1.45K |
-1.727x | -514.49% |
| 2002-03-31 | GBX46.21 Million ≈ $5.62K |
GBX-12.99 Million ≈ $-1.58K |
-0.281x | -135.96% |
| 2001-03-31 | GBX35.96 Million ≈ $4.38K |
GBX-4.28 Million ≈ $-521.24 |
-0.119x | -144.44% |
| 2000-03-31 | GBX41.55 Million ≈ $5.06K |
GBX-2.02 Million ≈ $-246.38 |
-0.049x | +86.06% |
| 1999-03-31 | GBX4.11 Million ≈ $499.95 |
GBX-1.44 Million ≈ $-174.72 |
-0.349x | +35.64% |
| 1998-03-31 | GBX2.52 Million ≈ $306.98 |
GBX-1.37 Million ≈ $-166.69 |
-0.543x | -77.10% |
| 1997-03-31 | GBX3.12 Million ≈ $379.37 |
GBX-956.00K ≈ $-116.32 |
-0.307x | -146.61% |
| 1996-03-31 | GBX678.00K ≈ $82.49 |
GBX446.00K ≈ $54.27 |
0.658x | +112.42% |
| 1995-03-31 | GBX44.00K ≈ $5.35 |
GBX-233.00K ≈ $-28.35 |
-5.295x | -4754.17% |
| 1994-03-31 | GBX330.00K ≈ $40.15 |
GBX-36.00K ≈ $-4.38 |
-0.109x | -- |
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast… Read more